Zobrazit v EDS

Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)

Uloženo v:
Podrobná bibliografie
Název: Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)
Autoři: Dittner-Moormann, Sabine, Reschke, Madlen, Abbink, Floor, AERTS, isabelle, Atalay, Hatice Tuba, Fedorovna Bobrova, Nadezhda, Sábado Álvarez, Constantino
Přispěvatelé: Institut Català de la Salut, Dittner-Moormann S Department of Pediatric Hematology and Oncology, University Duisburg-Essen, University Hospital Essen, Essen, Germany. Reschke M Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany. Abbink FCH Amsterdam UMC, Location VU University Medical Centre, Amsterdam, The Netherlands. Aerts I Institut Curie, PSL Research University and University of Paris, Paris, France. Atalay HT Gazi University School of Medicine, Ankara, Turkey. Fedorovna Bobrova N Filatov Eye Institute Odessa, Odessa, Ukraine. Sábado Álvarez C Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus
Zdroj: Scientia
Informace o vydavateli: Wiley
Rok vydání: 2021
Témata: Retina - Càncer - Quimioteràpia, Retina - Càncer - Radioteràpia, Enquestes, DISEASES::Neoplasms::Neoplasms::Neoplasms::Neoplasms::Neoplasms by Site::Eye Neoplasms::Retinal Neoplasms::Retinoblastoma, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires, ENFERMEDADES::neoplasias::neoplasias::neoplasias::neoplasias::neoplasias por localización::neoplasias del ojo::neoplasias de la retina::retinoblastoma, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios
Popis: Chemotherapy; Childhood cancer; Radiotherapy ; Quimioterapia; Cáncer infantil; Radioterapia ; Quimioteràpia; Càncer infantil; Radioteràpia ; Introduction Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. Method Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma Group (EURbG) network. Extended information was gathered via personal email communication. Results Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. Conclusion Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers. ; Open access funding enabled and organized by Projekt DEAL.
Druh dokumentu: article in journal/newspaper
Popis souboru: application/pdf
Jazyk: English
ISSN: 33720495
Relation: Pediatric Blood & Cancer;68(6); https://doi.org/10.1002/pbc.28963; Dittner‐Moormann S, Reschke M, Abbink FCH, Aerts I, Atalay HT, Fedorovna Bobrova N, et al. Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). Pediatr Blood Cancer. 2021 Jun;68(6):e28963.; https://hdl.handle.net/11351/7617; 000628887900001
DOI: 10.1002/pbc.28963
Dostupnost: https://hdl.handle.net/11351/7617
https://doi.org/10.1002/pbc.28963
Rights: Attribution-NonCommercial 4.0 International ; http://creativecommons.org/licenses/by-nc/4.0/ ; info:eu-repo/semantics/openAccess
Přístupové číslo: edsbas.71295B85
Databáze: BASE
Popis
Abstrakt:Chemotherapy; Childhood cancer; Radiotherapy ; Quimioterapia; Cáncer infantil; Radioterapia ; Quimioteràpia; Càncer infantil; Radioteràpia ; Introduction Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. Method Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma Group (EURbG) network. Extended information was gathered via personal email communication. Results Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. Conclusion Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers. ; Open access funding enabled and organized by Projekt DEAL.
ISSN:33720495
DOI:10.1002/pbc.28963